![]() | ![]() |
Formats:
|
||||||||||||
Copyright © 2005, Cold Spring Harbor Laboratory Press Genome-wide RNAi screen reveals a specific sensitivity of IRES-containing RNA viruses to host translation inhibition 1Harvard Medical School and Howard Hughes Medical Instutite, Department of Genetics, Boston Massachusetts 02115, USA; 2Stanford University School of Medicine, Department of Microbiology and Immunology, Stanford, California 94305, USA; 3Harvard Medical School, Department of Microbiology and Molecular Genetics, Boston Massachusetts 02115, USA 4Corresponding author. E-MAIL scherry/at/genetics.med.harvard.edu; FAX (617) 432-7688. Received September 30, 2004; Accepted December 16, 2004. This article has been cited by other articles in PMC.Abstract The widespread class of RNA viruses that utilize internal ribosome entry sites (IRESs) for translation include poliovirus and Hepatitis C virus. To identify host factors required for IRES-dependent translation and viral replication, we performed a genome-wide RNAi screen in Drosophila cells infected with Drosophila C virus (DCV). We identified 66 ribosomal proteins that, when depleted, specifically inhibit DCV growth, but not a non-IRES-containing RNA virus. Moreover, treatment of flies with a translation inhibitor is protective in vivo. Finally, this increased sensitivity to ribosome levels also holds true for poliovirus infection of human cells, demonstrating the generality of these findings. Keywords: Drosophila C virus, Drosophila, ribosome, translation, picornavirus, dicistroviridae Viruses are obligate intracellular pathogens and must perform certain steps in order to complete their life cycle, including entry into the cytoplasm of the host cell, uncoating, translation, replication, and virion assembly. Although all viruses must complete these steps, different families have developed radically different strategies to do so. As one consequence of their small genome size, all viruses require host-encoded proteins to replicate. The identification of host proteins and pathways co-opted by viruses to complete their life cycles has given us insights into both host–pathogen interactions and into the normal function of the implicated cellular systems. Not only do viruses need host factors to replicate, but they must also compete directly with the host cell for factors. For example, all viruses use the host-encoded translation machinery, including the ribosome, to translate their genomes (Bushell and Sarnow 2002). In order to successfully vie for host ribosomes and the limited pool of initiation factors, many viruses prevent host-encoded mRNAs from accessing ribosomes. Specifically, internal ribosome entry sites (IRES)-containing viruses have evolved a sophisticated translation mechanism that bypasses the requirement for the 5′ mGppp cap (a characteristic of host mRNAs), and instead utilizes a highly structured RNA sequence, which allows cap-independent recruitment of ribosomes to the viral RNA (Hellen and Sarnow 2001). Although different IRESs use diverse mechanisms to bring ribosomes to the viral genome, they all bypass some steps required for the translation of host-encoded messages, which in turn allows viral and host messages to be modulated differentially (Pestova et al. 2001). For example, by inactivating the eIF-4F complex that is required for capped host mRNAs to load onto the ribosome, polioviruses are able to inhibit the translation of host messages without affecting IRES-dependent translation (Hellen and Sarnow 2001). Because these viruses use this unique mechanism for translation, it has been hypothesized that specific inhibitors of IRES-dependent translation could be therapeutic for viral infections. However, such interventions have yet to materialize. The identification of those host factors that are required or limiting for IRES-dependent translation may allow more directed screens for small molecules that inhibit IRES function. That viral replication factors encoded by the host instead of the virus can be used as therapeutic targets has traditionally been unexplored. However the recent development of anti-CCR5 agents for treatment of HIV infection establishes the potential of this complementary approach (Shaheen and Collman 2004). Despite the demonstrable value of information on host factors involved in viral infection, our ability to identify these factors has been hampered by the dearth of amenable forward genetic systems. Drosophila has been widely used as a model to study development, cell biology, and innate immunity due to its powerful genetics and conservation with vertebrate systems. The full-genome sequence of Drosophila along with the development of RNAi technology permits the systematic survey of the phenotypic consequences of transcript depletion. This tool, when applied in a global, unbiased way, provides an in vitro genetic system that can be used to study the effects of gene knockdown on any system that can be adapted to high-throughput screening. We have previously developed a genome-wide set of Drosophila double-stranded RNA (dsRNA) reagents (Boutros et al. 2004). Here we have extended the use of this methodology to identify host factors that are essential for growth and replication of Drosophila C virus (DCV). DCV is an IRES-containing RNA virus that is a natural pathogen of Drosophila and can infect both flies and tissue culture cells, leading to lethality (Cherry and Perrimon 2004). This family of viruses includes many human pathogens including the picornaviruses poliovirus, Rhinovirus, and Hepatitis A virus as well as flaviviruses such as Hepatitis C virus (Knipe and Howley 2001). While these mammalian viruses have one IRES at the 5′ end of the genome, DCV along with other dicistroviridae have two IRESs (Johnson and Christian 1998). Despite this difference, these insect viruses share many physical and morphological properties with mammalian picornaviruses (King and Moore 1988; Johnson and Christian 1998; Tate et al. 1999). Moreover, where studied, the infectious cycle of DCV resembles that of pathogenic IRES-containing mammalian viruses (Scotti et al. 1981; Reavy and Moore 1983; Moore et al. 1985; King and Moore 1988). The recent use of DCV to identify a set of host factors required for viral entry found conserved proteins involved in clathrin-mediated endocytosis (Cherry and Perrimon 2004). Such experience suggested to us that the system is sensitive and has high conservation with mammalian viral biology. Consequently, we proposed, first, that this virus–host pair would be amenable to a genome-wide RNAi approach, and second, that any factors we discover to be required for DCV replication may also be important for the life cycle of related mammalian viruses. To dissect the cellular requirements for DCV replication, we undertook a genome-wide screen in tissue culture for host factors that, when lost, block viral infection. Using this strategy we identified the ribosome as limiting during infection. While the hypomorphic consequences of ribosomal protein depletion are tolerated, the cells become refractory to viral infection by DCV. In contrast, a non-IRES-containing virus is able to infect and replicate within these ribosome-depleted cells. This defect in the replication of DCV is mediated by a deficiency in translation from both IRESs present in DCV, suggesting that there may a general requirement for high levels of ribosomes for efficient translation from an IRES. Furthermore, the feeding of adult flies with a small molecule inhibitor of ribosomal function is protective in vivo. And most importantly, poliovirus infection was also attenuated by depletion of ribosomal proteins in human cells, demonstrating that attenuation of the translation apparatus may be a fruitful target for antiviral therapeutics. Results Genome-wide RNAi screen To identify host factors required for viral infection in Drosophila cell culture we designed a sensitive and quantitative assay for viral replication that was responsive to RNAi. We used these conditions to perform a genome-wide screen of ~21,000 dsRNA covering 91% of the genes predicted by both the Berkeley Drosophila Genome Project (BDGP) and the Sanger Center (Boutros et al. 2004). dsRNAs are aliquoted into 384-well plates, with each plate containing controls. We used a dsRNA generated against viral sequences as a positive control as DCV is an RNA virus and therefore the viral genome is susceptible to RNAi mediated degredation. As a negative control we generated dsRNA against gfp because it is not present in our system. Cells were treated with dsRNA for 3 d and then were infected with DCV at a multiplicity of infection (MOI) of 1, and 24 h post-infection the cells were stained with a polyclonal FITC-conjugated anti-capsid antibody and a nuclear counterstain (Fig. 1A
Attenuation of ribosome severely blocks viral replication These genes fall into a number of functional categories (Fig. 1C dsRNA against ribosomal proteins led to a significant and reproducible reduction in viral infection as measured by immunofluorescence (Figs. (Figs.1B,1B
Ribosomal proteins are reduced upon loss of a single component Consistent with the assumption that dsRNAs targeting the ribosome affect the complement of ribosomal proteins in the cell, we found that RNAi against RpS6 leads to a reduction in RpS6 protein levels (Fig. 2B Given that the previous experiment only tested the steady-state levels of host protein synthesis under these hypomorphic conditions we also tested whether general host translation is affected using an S35 methionine-pulse post-RNAi. We treated cells with dsRNA against either a control or RpS6 or RpL19 and pulsed the cells for 1 h. We found that there was a less than twofold decrease in host protein translation under these conditions while cycloheximide treatment decreases incorporation by >10-fold (Fig. 2C To determine whether this depletion of ribosomal proteins was at the level of protein or RNA we analyzed total RNA levels of RpL19 in cells depleted for different ribosomal proteins or a gfp control. While we observed a loss in RpS6 protein levels in cells treated with dsRNA against RpL19, we observed no effect on RpS6 RNA levels (Fig. 2D This suggests that the loss of a single ribosomal protein can lead to a specific decrease in other ribosomal protein levels in the absence of an overt effect on the cell's protein complement. That levels of ribosomal proteins are affected in trans by the loss of one component is, to our knowledge, a novel finding. Hypomorphic depletion of ribosome is tolerated by cells That there are only small global effects on the cells, as measured by S35 methionine incorporation or alpha-tubulin levels, is consistent with our findings that RNAi against these ribosomal proteins did not lead to an increase in cell death as measured by membrane permeability (Fig. 2E VSV replication is unaffected by dsRNA against the ribosome Given that translation is fundamental to cellular function, one possibility is that, while the cells remain viable, they are not able to support viral replication for independent reasons. For example, in mammals, a general anti-viral response involves the global inhibition of host translation by preventing translation of both cellular and viral mRNAs (Samuel 2001). Clearly the overall abundance of host proteins or tubulin was not largely affected by the various RNAi treatments. To more rigorously examine global effects on viral replication, we tested whether Vesicular Stomatitis virus (VSV), an unrelated enveloped negative-stranded RNA virus that has both mammalian and insect hosts, was able to replicate in cells depleted for these ribosomal proteins (Knipe and Howley 2001). Using recombinant VSV that expresses Gfp upon replication at an MOI of 1, we found that loss of ribosomal proteins had a negligible effect on viral infection, whereas treatment with dsRNA against Rab5, a protein required for endocytosis and viral entry, protected the cells from VSV infection (Fig. 3A
Ribosomal depletion specifically blocks IRES-dependent translation Therefore, the specific requirement of DCV for wild-type levels of ribosomal proteins suggests that DCV may have a unique requirement for the cellular translation apparatus. One specialized feature of DCV is that its mRNA is not translated by a 5′ cap-dependent translation mechanism as are most eukaryotic and VSV mRNAs, but by an internal ribosomes entry mechanism that is employed by various viral and a few cellular mRNAs (Wilson et al. 2000; Hellen and Sarnow 2001; Knipe and Howley 2001). Internal ribosome entry is mediated by an RNA element that is usually hundreds of nucleotides in length (Hellen and Sarnow 2001). While mammalian picornaviruses have one IRES element that directs the synthesis of one polyprotein, DCV along with other dicistroviridae have two IRESs depicted in Figure 3B To test whether the defect in viral replication was indeed due to a direct effect on translation from the viral IRESs we used a bicistronic vector system (Johannes et al. 1999). The first cistron directs the cap-dependent translation of Renilla luciferase, while the second cistron mediates the cap-independent, IRES-dependent translation of firefly luciferase (Fig. 3C Based on analogy to picornaviruses, one would predict that DCV infection results in inhibition of host translation by a mechanism to which the virus itself is insensitive. To examine this, we infected cells with DCV and pulse-labeled with S35 methionine at different times post-infection. By 12 h post-infection, translation from host mRNAs is inhibited while viral RNA continues to be translated (Fig. 3E Drug treatment in vivo attenuates infection Given that attenuation of ribosome function protects cultured cells from DCV infection, we tested whether the general translation inhibitor Hygromycin B could protect flies from DCV infection (Brodersen et al. 2000). We fed adult flies serial dilutions of sublethal doses of the aminoglycoside eukaryotic ribosomal inhibitor Hygromycin B and then challenged them with DCV. We monitored the flies' susceptibility to infection and found that the drug causes a dose-dependent inhibition of virus-induced lethality. At concentrations between ~17.5 and 280 μM we observed protection from DCV infection in the absence of drug toxicity (Fig. 4A
Poliovirus infection is also sensitive to levels of translation apparatus Because attenuation of the ribosome inhibited translation from both IRESs present in DCV, we hypothesized that this effect may be generalizable to mammalian IRES-containing viruses such as poliovirus. The two IRESs present in DCV are quite different from one another and are thought to use different mechanisms for translation initiation (Pestova et al. 2001). To test whether attenuation of the ribosome could also protect human cells from an IRES-containing virus, we infected cultured human cells pretreated with an siRNA against RpS6 with poliovirus at an MOI of 4. We observed a 10-fold reduction of viral titers in cells transfected with an siRNA against RpS6 compared to a control siRNA (Fig. 4B Discussion These findings demonstrate that both insect and mammalian IRES-containing RNA viruses are unusually sensitive to levels of the ribosomal machinery. Consistent with our observation that attenuation of the ribosome can be tolerated by cells, it has been reported that many yeast ribosomal subunits are dispensable for growth, and likewise conditional mutation of RpS6 in the mouse liver has no effect on hepatocyte viability or translation even though there is a reduction in the production of 40S ribosomal complexes (Volarevic et al. 2000; Giaever et al. 2002). Moreover, zebrafish carrying heterozygous mutations in a number of ribosomal proteins are predisposed to cancer (Amsterdam et al. 2004). How the loss of ribosomal proteins leads to different phenotypic consequences is presently unclear. However, the fact that ribosomal inhibition can be tolerated in vitro, together with the fact that pharmacologic inhibition of translation protects from DCV infection in vivo, suggests a novel approach to viral inhibition. Whereas poliovirus had until recently been considered conquered, the recent poliomyelitis outbreak in West Africa gives new urgency to the search for therapeutics for this disease. Furthermore, given that additional IRES-dependent viruses, including Hepatitis C virus and rhinovirus, are widespread human pathogens that are also currently without efficacious treatments, our data suggest that modulating host ribosome activity could be a promising new direction for antiviral drug discovery. Material and methods Cells and virus Schneider line 2 cells were maintained as described (Cherry and Perrimon 2004). DCV was purified and titered as described (Cherry and Perrimon 2004). An infectious cDNA clone of VSV was engineered to contain an additional transcriptional unit encoding gfp, generating VSV-gfp. The gfp ORF was amplified by PCR from pGreenlantern (Invitrogen) and inserted between conserved VSV gene-start end sequences engineered at the leader-N gene junction. VSV-gfp was recovered, purified, and titered as described (Whelan et al. 1995). dsRNA treatments dsRNA was generated as described (Boutros et al. 2004). The cells were plated at 20,000 cells per well in 10 μL serum-free media into 384-well plates pre-aliquoted with 250 ng of dsRNA. One hour later 20 μL of complete media were added (Clemens et al. 2000). Cells were used 3 d later. Viral infections Three days post-dsRNA addition cells were infected with DCV at a MOI of 1. DCV was prepared as previously described (Cherry and Perrimon 2004). One day later the cells were fixed and stained with FITC-conjugated anti-capsid DCV and counterstained with Hoescht 33342 as described (Cherry and Perrimon 2004). Images were captured using an automated microscope as described and analyzed using Metamorph software (Kiger et al. 2003). For viral titers, supernatant was removed before fixing the cells and serial dilutions were used to infect cells. The highest dilution that resulted in positive infection by immunofluorescence was considered the titer of the sample. Three days post-dsRNA cells were infected with VSV-gfp at a MOI of 1. Twenty-four hours later the cells were fixed and stained as above. Protein analysis Western blot analysis was performed as described (Cherry and Perrimon 2004) using using anti-RPS6 (Cell Signaling, 1:200) or anti-Tubulin (Sigma, 1:2000). For total protein analysis cells were pulsed with S35 methionine (NEN) for 2 h at the indicated time points post-infection with DCV. Total cell lysates were prepared as above and run on a 10% SDS-Page gel and visualized using fluorography. For S35 methionine incorporation cells treated with dsRNA or siRNAs were pulsed for 1 h or 20 min, respectively, with S35 methionine (NEN) and prepared as above. Total cell lysate was precipitated with 10% trichloroacetic acid and quantitated using a scintillation counter. Northern blot analysis Total RNA was extracted from dsRNA-treated cells using Trizol following the manufacturer's protocol. Ten micrograms RNA were run on a 1% gel and transferred to Hybond-N+ nylon and a radiolabeled probe was generated from the PCR product used for dsRNA production. Hybridization was carried out with Church buffer as recommended. Cell death analysis Three days post-dsRNA cells were analyzed for cell death by staining with Sytox (Molecular Probes, 1:5000) and Hoescht 33342 for 10 min. The samples were washed twice in PBS before images were collected and analyzed. Luciferase assays IRES1 was cloned by PCR using primers 5′-AGAATTCTT TATATCGTGTGTACATATAAATA-3′ and 5′-CATGCCAT GGTTATCGTTAAGCGCAAGATC-3′ (nucleotides 1–796) and IRES2 using 5′-CATGCCATGGTTGTTTGAAAGTTAG CAGGTT-3′ and 5′-CGGAATTCTTAAGATGTGATCTTGC TT-3′ (nucleotides 6080–6282); these primers contain EcoRI and NcoI restriction sites that were used to clone these into the intercistronic region of a bicistronic luciferase reporter vector (c53/Delta EMCV) and subcloned into pACTpl to express in Drosophila cells. Cells (150,000) were cotransfected with 0.1 μg of bicistronic vector plus 0.1 μg dsRNA with Effectene (Qiagen) using the manufacturer's protocol. Five days post-transfection the cells were assayed using Dual-glo luciferase reagents (Promega) following the manufacturer's protocol and quantitated using an Analyst GT plate reader (Molecular Devices). Feeding experiments Groups of 25 flies were placed on standard media plus serial dilutions of Hygromycin B (17.5–280 μM; Calbiochem) 1 d prior to infection. They were infected with ~5 × 104 virions by injection and monitored daily (Cherry and Perrimon 2004). Poliovirus infections HeLa cells were cultured in antibiotic-free DMEM medium, supplemented with 10% FBS and L-glutamine. Seventy-five percent confluent cultures were transfected with 10 pmol RpS6 siRNA (Dharmacon) or randomized control siRNA in 100 μL transfection media consisting of OptiMEMI and Lipofectamine 2000 in an eight-chamber dish. After a 2-h incubation at 37°C, 200 μL media were added to each well to yield a final siRNA concentration of 100 nM in a final volume of 0.3 mL. After 45 h of transfection, the medium was removed and cells were infected with poliovirus at a MOI of 4 in a total volume of 100 μL. After a 30-min incubation at 37°C medium was added and cells were incubated for an additional 4 h at 37°C. Virus was harvested and viral yield was determined by plaque assay as described (Johnson and Sarnow 1991). Acknowledgments We thank Matthew Tudor and Jennifer Philips for helpful discussions, Christians Villalta for microinjections, and the Drosophila RNAi Screening Center for providing expertise and the facilities for screening. This work was supported by NIH grants AI051365, AI10532, and GM55979. Notes Supplemental material is available at http://www.genesdev.org. Article and publication are at http://www.genesdev.org/cgi/doi/10.1101/gad.1267905. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||
J Cell Biol. 2002 Aug 5; 158(3):395-9.
[J Cell Biol. 2002]Genes Dev. 2001 Jul 1; 15(13):1593-612.
[Genes Dev. 2001]Proc Natl Acad Sci U S A. 2001 Jun 19; 98(13):7029-36.
[Proc Natl Acad Sci U S A. 2001]Curr Opin Infect Dis. 2004 Feb; 17(1):7-16.
[Curr Opin Infect Dis. 2004]Science. 2004 Feb 6; 303(5659):832-5.
[Science. 2004]Nat Immunol. 2004 Jan; 5(1):81-7.
[Nat Immunol. 2004]J Gen Virol. 1998 Jan; 79 ( Pt 1)():191-203.
[J Gen Virol. 1998]Nat Struct Biol. 1999 Aug; 6(8):765-74.
[Nat Struct Biol. 1999]Adv Virus Res. 1981; 26():117-43.
[Adv Virus Res. 1981]Arch Virol. 1983; 76(2):101-15.
[Arch Virol. 1983]Science. 2004 Feb 6; 303(5659):832-5.
[Science. 2004]Nat Immunol. 2004 Jan; 5(1):81-7.
[Nat Immunol. 2004]Science. 2004 Feb 6; 303(5659):832-5.
[Science. 2004]Clin Microbiol Rev. 2001 Oct; 14(4):778-809, table of contents.
[Clin Microbiol Rev. 2001]Traffic. 2003 May; 4(5):333-43.
[Traffic. 2003]Mol Cell Biol. 2000 Jul; 20(14):4990-9.
[Mol Cell Biol. 2000]Genes Dev. 2001 Jul 1; 15(13):1593-612.
[Genes Dev. 2001]J Gen Virol. 1998 Jan; 79 ( Pt 1)():191-203.
[J Gen Virol. 1998]Proc Natl Acad Sci U S A. 2001 Jun 19; 98(13):7029-36.
[Proc Natl Acad Sci U S A. 2001]Nat Immunol. 2004 Jan; 5(1):81-7.
[Nat Immunol. 2004]Proc Natl Acad Sci U S A. 1999 Nov 9; 96(23):13118-23.
[Proc Natl Acad Sci U S A. 1999]Mol Cell Biol. 2000 Jul; 20(14):4990-9.
[Mol Cell Biol. 2000]Cell. 2000 Dec 22; 103(7):1143-54.
[Cell. 2000]Proc Natl Acad Sci U S A. 2001 Jun 19; 98(13):7029-36.
[Proc Natl Acad Sci U S A. 2001]Science. 2000 Jun 16; 288(5473):2045-7.
[Science. 2000]Nature. 2002 Jul 25; 418(6896):387-91.
[Nature. 2002]PLoS Biol. 2004 May; 2(5):E139.
[PLoS Biol. 2004]Nat Immunol. 2004 Jan; 5(1):81-7.
[Nat Immunol. 2004]Proc Natl Acad Sci U S A. 1995 Aug 29; 92(18):8388-92.
[Proc Natl Acad Sci U S A. 1995]Science. 2004 Feb 6; 303(5659):832-5.
[Science. 2004]Proc Natl Acad Sci U S A. 2000 Jun 6; 97(12):6499-503.
[Proc Natl Acad Sci U S A. 2000]Nat Immunol. 2004 Jan; 5(1):81-7.
[Nat Immunol. 2004]J Biol. 2003; 2(4):27.
[J Biol. 2003]Nat Immunol. 2004 Jan; 5(1):81-7.
[Nat Immunol. 2004]Nat Immunol. 2004 Jan; 5(1):81-7.
[Nat Immunol. 2004]J Virol. 1991 Aug; 65(8):4341-9.
[J Virol. 1991]Nucleic Acids Res. 2003 Jan 1; 31(1):172-5.
[Nucleic Acids Res. 2003]